Revolution Medicines (RVMD) FCF Margin (2019 - 2023)

Revolution Medicines' FCF Margin history runs 5 years deep, the most recent figure standing at 16421.16% for Q4 2023.

• In Q4 2023, FCF Margin fell 1606064.0% year-over-year to 16421.16%; the TTM figure through Sep 2024 stood at 74134.37% (down 7303912.0% YoY), while the FY2023 annual figure was 3049.94%, down 241167.0% from the prior year.
• FCF Margin was 16421.16% for Q4 2023 at Revolution Medicines, down from 1784.52% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 97.44% in Q4 2019 to a low of 16421.16% in Q4 2023.
• Historically, FCF Margin has averaged 1497.75% across 5 years, with a median of 376.35% in 2021.
• The sharpest annual moves came in 2022 and 2023: FCF Margin soared 161463 bps in 2022, then sank 1606064 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 97.44% in 2019, then tumbled by 210 bps to 301.75% in 2020, then slumped by 60 bps to 483.6% in 2021, then rose by 25 bps to 360.52% in 2022, then tumbled by 4455 bps to 16421.16% in 2023.
• The last three FCF Margin figures came in at 16421.16% (Q4 2023), 1784.52% (Q2 2023), and 914.59% (Q1 2023), per Business Quant data.